Insider Selling: ANI Pharmaceuticals (NASDAQ:ANIP) SVP Sells 1,763 Shares of Stock

Key Points

• Krista Davis, Senior Vice President of ANI Pharmaceuticals, sold 1,763 shares at an average price of $91.10, reducing her ownership by 2.73% and leaving her with approximately 62,896 shares valued at about $5.73 million.
• ANI Pharmaceuticals reported $1.80 earnings per share for the last quarter, exceeding estimates by $0.38, with quarterly revenue up 53.2% year-over-year.
• Analysts currently have an average price target of $84.75 for ANI Pharmaceuticals, with the stock rated predominantly as a Buy or Strong Buy by several research firms.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) SVP Krista Davis sold 1,763 shares of the firm's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $91.10, for a total value of $160,609.30. Following the completion of the transaction, the senior vice president directly owned 62,896 shares in the company, valued at $5,729,825.60. This trade represents a 2.73% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

ANI Pharmaceuticals Stock Up 1.0%

NASDAQ:ANIP traded up $0.97 during mid-day trading on Friday, hitting $93.50. The company had a trading volume of 283,240 shares, compared to its average volume of 751,359. The business has a fifty day simple moving average of $73.39 and a 200-day simple moving average of $67.02. The company has a current ratio of 2.54, a quick ratio of 1.96 and a debt-to-equity ratio of 1.39. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $93.72. The firm has a market capitalization of $2.03 billion, a price-to-earnings ratio of -121.43 and a beta of 0.61.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its quarterly earnings data on Friday, August 8th. The specialty pharmaceutical company reported $1.80 EPS for the quarter, beating the consensus estimate of $1.42 by $0.38. The company had revenue of $211.37 million for the quarter, compared to analyst estimates of $187.18 million. ANI Pharmaceuticals had a positive return on equity of 25.03% and a negative net margin of 1.37%.The firm's revenue was up 53.2% compared to the same quarter last year. During the same period last year, the company posted $1.02 earnings per share. Equities analysts forecast that ANI Pharmaceuticals, Inc. will post 3.86 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ANI Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. CANADA LIFE ASSURANCE Co grew its holdings in shares of ANI Pharmaceuticals by 1.0% during the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 19,408 shares of the specialty pharmaceutical company's stock valued at $1,267,000 after acquiring an additional 198 shares in the last quarter. Hohimer Wealth Management LLC grew its holdings in shares of ANI Pharmaceuticals by 5.2% during the 1st quarter. Hohimer Wealth Management LLC now owns 4,989 shares of the specialty pharmaceutical company's stock valued at $334,000 after acquiring an additional 247 shares in the last quarter. Thrivent Financial for Lutherans lifted its stake in shares of ANI Pharmaceuticals by 2.6% in the 2nd quarter. Thrivent Financial for Lutherans now owns 12,511 shares of the specialty pharmaceutical company's stock valued at $816,000 after purchasing an additional 321 shares during the last quarter. Legal & General Group Plc lifted its stake in shares of ANI Pharmaceuticals by 0.8% in the 2nd quarter. Legal & General Group Plc now owns 46,712 shares of the specialty pharmaceutical company's stock valued at $3,048,000 after purchasing an additional 351 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of ANI Pharmaceuticals by 3.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 10,523 shares of the specialty pharmaceutical company's stock valued at $582,000 after purchasing an additional 364 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently weighed in on ANIP shares. Guggenheim restated a "buy" rating and set a $86.00 target price on shares of ANI Pharmaceuticals in a research note on Monday, May 12th. Zacks Research upgraded ANI Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research note on Thursday, August 21st. HC Wainwright reiterated a "buy" rating and issued a $93.00 price target (up from $84.00) on shares of ANI Pharmaceuticals in a research note on Friday, August 8th. Truist Financial lifted their price target on ANI Pharmaceuticals from $65.00 to $77.00 and gave the stock a "hold" rating in a research note on Monday, August 11th. Finally, Wall Street Zen upgraded ANI Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research note on Saturday, August 16th. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average target price of $84.75.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.